Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Pfizer discontinues Trubion's TRU-015 for rheumatoid arthritis

This article was originally published in Scrip

Executive Summary

Pfizer has discontinued development of Trubion Pharmaceuticals' TRU-015, which was in Phase II development for the treatment of rheumatoid arthritis under the companies' CD20 collaboration. However, it intends to continue development of a follow-on compound, SBI-087.

You may also be interested in...



Pfizer Pays Out On Rituximab Biosimilar

Agreements signed between Wyeth and Trubion Pharmaceuticals more than a decade ago have led to Pfizer making royalty payments on its rituximab biosimilar, Ruxience, to Aptevo Therapeutics.

UK Reimbursement Decisions Focus Mostly On Cancer

The UK's main reimbursement bodies made a series of decisions this week that were broadly favorable and largely focused on oncology medicines.

Deal Watch: Valeant Sells Off iNova To Finance Debt-Reduction Efforts

While troubled Valeant was divesting iNova to private equity investors, Novartis announced a pair of oncology-focused deals, out-licensing a brain cancer drug to Midatech and partnering with IBM Watson Health to optimize breast cancer treatment.

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

SC009161

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel